ResMed insider Michael Farrell plans $1.1M sale
RESMED INC (RMD) received a Rule 144 notice for a proposed sale of common stock for the account of Michael J. Farrell.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RESMED INC (RMD) received a Rule 144 notice for a proposed sale of common stock for the account of Michael J. Farrell. The filing covers 4,991 shares of common stock, with an indicated aggregate market value of $1,129,064.02, to be sold through Fidelity Brokerage Services LLC on or after September 8, 2026 on the NYSE, in connection with a stock option exercise for cash.
The notice also lists sales during the prior three months, each for 4,991 shares of common stock by Michael Farrell, on June 8, 2026 for $968,064.34, July 7, 2026 for $1,090,770.57, and August 7, 2026 for $1,026,596.29.
Key Figures
Key Terms
Rule 144 regulatory
stock option exercise financial
aggregate market value financial
attorney-in-fact regulatory
common stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Form 144 filing report for ResMed (RMD)?
Who is the insider involved in the ResMed (RMD) Form 144 filing?
What is the relationship between the proposed ResMed (RMD) sale and stock options?
Which broker is handling the proposed ResMed (RMD) Rule 144 sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.